Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism

• US 20060122270A1
• Filed: 01/13/2006
• Published: 06/08/2006
• Est. Priority Date: 05/01/2000
• Status: Abandoned Application

• Current Assignee: Accela Incorporated (Piksel Incorporated)
• Original Assignee: Accela Incorporated (Piksel Incorporated)
• Inventors: Henderson, Samuel T.
• Application Number:
  US11/331,673
• Publication Number:
  US 20060122270A1
• Time in Patent Office: Days
• US Class Current: 514/546
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/12 Ketones
• CPC Class Codes: A61K 31/20 having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
• CPC Class Codes: A61K 31/205 Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
• CPC Class Codes: A61K 31/215 of carboxylic acids
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61K 31/221 with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
• CPC Class Codes: A61K 31/23 of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• CPC Class Codes: A61K 31/25 with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer'"'"'s type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability.

Claims

1. A method of treating or preventing dementia of Alzheimer'"'"'s type, or other loss of cognitive function caused by reduced neuronal metabolism, comprising administering an effective amount of medium chain triglycerides to a patient in need thereof.

2. The method of claim 1, wherein said administration is oral.

3. The method of claim 1, wherein said administration is intravenous.

4. The method claim 1, wherein said medium chain triglycerides are administered medium chain triglycerides are administered at a dose of about 0.5 g/kg/day to about 10 g/kg/day.

5. The method of claim 1, further comprising coadministering L-carnitine or a derivative of L-carnitine.

6. The method claim 5, wherein said administration is oral, and said medium chain triglycerides are administered at a dose of about 0.5 g/kg/day to about 10 g/kg/day and said L-carnitine or said derivative of L-carnitine is administered at a dose of about 0.5 mg/kg/day to about 10 mg/kg/day.

7. The method of claim 1, wherein said medium chain triglycerides are emulsified.

8. The method of claim 7, further comprising coadministering L-carnitine or a derivative of L-carnitine.

9. The method of claim 8, wherein said emulsified medium chain triglycerides and L-carnitine or a derivative of L-carnitine are administered in a formulation comprising 10-500 g emulsified medium chain triglycerides and 10-2000 mg L-carnitine or derivative of L-carnitine.

10. A method of treating or preventing dementia of Alzheimer'"'"'s type, or other loss of cognitive function caused by reduced neuronal metabolism, comprising coadministering an effective amount of an agent selected from the group consisting of medium chain triglycerides, medium chain fatty acids, and ketone bodies, and L-carnitine or a derivative of L-carnitine to a patient in need thereof.

11. The method of claim 10, wherein said coadministration is intravenous, and said agent selected from the group consisting of medium chain triglycerides, medium chain fatty acids, and ketone bodies is administered at a dose of about 0.5 g/kg/day to about 10 g/kg/day and said L-carnitine or said derivative of L-carnitine is administered at a dose of about 0.5 mg/kg/day to about 10 mg/kg/day.

12. The method of claim 10, wherein said agent selected from the group consisting of medium chain triglycerides, medium chain fatty acids, and ketone bodies and L-carnitine or a derivative of L-carnitine are administered in a formulation comprising 10-500 g of said agent and 10-2000 mg L-carnitine or derivative of L-carnitine.